SCHEDULE: Goldman Sachs Discloses 5.1% Stake in Intellia Therapeutics
Beneficial Ownership Disclosure
Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, reported beneficial ownership of 5.1% of Intellia Therapeutics, Inc.'s common stock as of September 30, 2025.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly filed a Schedule 13G, disclosing beneficial ownership in Intellia Therapeutics, Inc.
- As of September 30, 2025, the reporting persons beneficially owned an aggregate of 5,498,262.38 shares of Intellia Therapeutics' common stock.
- This aggregate amount represents 5.1% of the class of securities.
- The reporting persons hold shared voting power over 5,497,802.38 shares and shared dispositive power over 5,497,897.38 shares.
- Neither reporting person holds sole voting power nor sole dispositive power over any shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as a Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the issuer's performance or prospects, beyond the implicit signal of a large institutional investment.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment by Goldman Sachs in Intellia Therapeutics, a company operating in the biotechnology sector, specifically known for its CRISPR-based gene editing therapies. Such a stake by a major financial institution can be viewed as a vote of confidence in the company's long-term prospects or its sector.
Stakeholder Impact
- Shareholders may view Goldman Sachs' 5.1% stake as a positive signal of institutional confidence in Intellia Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. superseded. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC superseded. |
| 2025-07-16 | New Power of Attorney granted by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, effective until July 16, 2026. |
| 2025-09-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-10-08 | Date of the joint filing agreement and signature date for the Schedule 13G. |
| 2026-07-16 | Expiration date of the current Power of Attorney. |
Recommendation
holdThe filing indicates a significant institutional stake by Goldman Sachs, suggesting confidence in Intellia Therapeutics. However, a Schedule 13G is a passive ownership disclosure and does not provide operational or financial performance details to warrant a 'buy' or 'sell' recommendation. Investors should consider this as a data point indicating institutional interest and continue to monitor the company's fundamentals and market conditions.
Keywords
Intellia Therapeutics, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, CRISPR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.